Alluvi, previously BI 4744, presents a notable breakthrough in obesity care. This dual agonist targeting both GLP-1 and GIP targets demonstrates compelling results in research assessments, potentially outperforming https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/